Merck (MRK) said Sunday its immunotherapy drug Keytruda improved by event-free survival by 34% in a phase 3 trial evaluating it as a perioperative treatment for patients with stage III or IVA resected locally advanced head and neck squamous cell carcinoma.
Median event-free survival in the study was 51.8 months to 59.7 months among patients treated with Keytruda in combination with radiotherapy compared 29.6 months to 30.4 months for those treated with radiotherapy alone, the biotech giant said.
Merck said it has a supplemental biologics license application for Keytruda based on the study under priority review with the US Food and Drug Administration with a target action date of June 23.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.